Prostate cancer (PCa) is the most common cancer in male in Westernized countries and is a clinically heterogeneous disease with substantial variability in progression. Emerging studies support a crucial role of metabolic plasticity of prostatic tumor cells with fatty acids and sterols being demonstrated to represent hallmarks of aggressiveness in PCa. In this context, targeting prostate cancer cell metabolism and more specifically lipid metabolism show great promise for developing alternative adjunct therapies to be used in combination with chemotherapy and androgen deprivation therapy. Moreover, alterations in the epigenome, due to modulation of histone and DNA modification enzymes that results from metabolic reprogramming driven by oncogenes and expression of metabolism-associated genes have been associated not only with neoplastic transformation, but also with cancer aggressive biology. The overall objective of our research and training network PROSTAMET, is to enhance the knowledge and understanding of metabolic changes that occur at the primary as well as the metastatic sites of prostate cancer in order to identify new markers of aggressiveness and/or new therapeutic targets related to lipid metabolism. Study of the lipid metabolism of tumor cells and the impact of cellular components of the microenvironment together with the design and assay of new pharmacological compounds will be used as a platform to develop an interdisciplinary training program on tumor aggressiveness, cell metabolism, structural biology, and the development of novel metabolism modulators. The overall goal of our project is to assemble a consortium of world-renown experts in prostate cancer, lipid metabolism and development/screening of novel anti-tumor drugs in order to train the new generation of young researchers involved in the field of cancer. Our consortium will combine research-based training in the field of metabolism, epigenetics and prostate cancer research and development together with training in relevant transferable skills such as IP management, communication, personal and career development and entrepreneurship into an Initial Training Network (ITN) proposal. To achieve this goal, we have assembled a core consortium of relevant experts with international repute. The MRSEI grant will allow us enlarging and consolidating this core consortium with additional complementary partners from the public and private sectors. Combining the skills in cancer research and analytics with industrial quality management and transferable skills will increase the chances of our early stage researchers of productive and successful careers in their chosen sectors.